BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded by Wall Street Zen to Buy Rating

Key Points

• Wall Street Zen upgraded BioMarin to “Buy” from “Hold,” while broader analyst coverage remains positive with a consensus “Moderate Buy” rating and an average price target of $87.86.
• BioMarin’s latest quarter beat expectations, with earnings of $1.20 per share versus $0.95 expected and revenue of approximately $989.7 million, up 20% year over year. The company guided to fiscal 2026 EPS of $4.90–$5.10.
• Institutional investors own 98.71% of the stock, with major funds including Viking Global Investors, Norges Bank and AQR Capital Management recently increasing or initiating positions.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

A number of other research firms also recently commented on BMRN. HC Wainwright raised their price objective on shares of BioMarin Pharmaceutical from $50.00 to $60.00 and gave the stock a "neutral" rating in a report on Friday. UBS Group reissued a "neutral" rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Bank of America dropped their price target on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a "buy" rating for the company in a research report on Tuesday, May 19th. Morgan Stanley raised their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an "overweight" rating in a research note on Friday. Finally, Weiss Ratings raised BioMarin Pharmaceutical from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $87.86.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ BMRN opened at $63.81 on Friday. The firm has a market capitalization of $12.33 billion, a price-to-earnings ratio of 172.46, a PEG ratio of 0.47 and a beta of 0.24. BioMarin Pharmaceutical has a one year low of $49.26 and a one year high of $66.28. The business has a fifty day simple moving average of $58.19 and a 200 day simple moving average of $57.06. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.36%. The business's revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Sell-side analysts expect that BioMarin Pharmaceutical will post 4.22 EPS for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in the company. Viking Global Investors LP grew its stake in BioMarin Pharmaceutical by 13.8% during the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company's stock worth $675,505,000 after buying an additional 1,488,552 shares during the last quarter. Norges Bank bought a new position in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $447,572,000. AQR Capital Management LLC boosted its holdings in shares of BioMarin Pharmaceutical by 12.7% in the 4th quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company's stock worth $395,197,000 after acquiring an additional 754,807 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of BioMarin Pharmaceutical by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company's stock worth $214,804,000 after acquiring an additional 481,176 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in BioMarin Pharmaceutical by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 3,674,089 shares of the biotechnology company's stock worth $218,395,000 after acquiring an additional 131,969 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations. BioMarin reported adjusted earnings of $1.20 per share versus the $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, ahead of estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook. Full-year adjusted EPS guidance increased to $4.90-$5.10 from a prior level below that range and above the roughly $4.80 consensus. Revenue guidance was set around $3.9 billion. Stronger-than-expected VOXZOGO sales and continued momentum in key therapies supported the revision. BioMarin Reports Second Quarter 2026 Results
• Positive Sentiment: Amicus additions could improve long-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, along with cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion and cash flow through the mid-2030s. BioMarin Lifts 2026 Outlook
• Positive Sentiment: Morgan Stanley raised its price target to $124 from $119 and maintained an Overweight rating, signaling substantial potential upside in its valuation view.
• Neutral Sentiment: HC Wainwright increased its target to $60 from $50 but retained a Neutral rating, indicating more cautious expectations than Morgan Stanley.
• Negative Sentiment: BioMarin discontinued a $270 million rare-disease asset after the treatment missed its Phase 3 endpoint. The setback removes a potential growth opportunity and highlights clinical-development risk. BioMarin Axes Rare-Disease Asset

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source